UNSPSC 51142542: Apomorphine diacetate

This classification denotes a dopamine agonist and antiparkinsonian agent C21H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1USW70QZGV, chemically known as (6ar)-5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo(de,g)quinoline-10,11-diol diacetate (ester), but more generally known as apomorphine diacetate, which bears US NIH Compound Identifier 201536. Most nations, for tariff and trade purposes, schedule apomorphine diacetate under HS 29391900 and SITC 54141.

As of Q4 2014, APOMORPHINE DIACETATE remains US FDA's Preferred Term for this commodity. Apomorphine diacetate bears US NLM identifiers UMLS ID C2827080 and NCI Concept Code C83535. SMILES: CC(=O)OC1CCC2C(C1OC(=O)C)-C3CCCC4C3[C@@H](C2)N(CC4)C.

UNSPSC 51142542 Apomorphine diacetate is a Commodity code capturing pharmaceutical products purchased by state and local health agencies, though recent state and local solicitation activity under this code does not directly feature apomorphine diacetate itself. Instead, the opportunities tagged to this code reflect broader pharmaceutical procurement by public health systems — including naloxone (opioid antagonist), over-the-counter medications, and multi-source generic pharmaceuticals distributed through state cooperative purchasing arrangements. State and local issuing bodies pursuing these products include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Vendors supplying under this code must meet cGMP certification, Drug Supply Chain Security Act compliance, FDA approval, and insurance requirements (including workers' compensation, commercial general liability, and professional liability coverage). Contracts typically run two years with renewal options and require established relationships with authorized wholesalers or direct-to-manufacturer capabilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on April 3, 2026 to explore vendor capabilities for a direct-to-manufacturer prescription program, soliciting information from potential suppliers about direct contracting capacity and value-based agreement models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) closing March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026 and evaluation weighted heavily toward price competitiveness (75 percent) and compliance with administrative and EDI requirements.